Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 13.57% is 10% below its 5-year average of 15.11%, around the middle of its 5-year range (4.81%–22.32%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.24% above its 12-month average of 13.02%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 13.57%.
DEBT TO ASSETS RATIO
13.57%
DEBT TO ASSETS RATIO AVG TTM
13.02%
DEBT TO ASSETS RATIO AVG 3Y
14.69%
DEBT TO ASSETS RATIO AVG 5Y
15.11%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+4.24%
CURRENT VS 3Y AVG
-7.59%
CURRENT VS 5Y AVG
-10.17%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+14980.95%
vs the sector median at left
Black Diamond Therapeutics, Inc.
Market Cap
$103.14M
Debt to Assets Ratio
13.57%
TTM Avg
13.02%
3Y Avg
14.69%
5Y Avg
15.11%
Market Cap
$102.75M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.26M
Debt to Assets Ratio
0.34%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.68M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$99.62M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.93M
Debt to Assets Ratio
0.43%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.96M
Debt to Assets Ratio
0.70%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | $103.14M | 13.57% | 13.02% | 14.69% | 15.11% |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.75M | 0.01% | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.26M | 0.34% | N/A | N/A | N/A |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | 0.00% | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $101.36M | 0.04% | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $106.52M | 0.00% | N/A | N/A | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $99.62M | 0.01% | N/A | N/A | N/A |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | 0.43% | N/A | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | 0.70% | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | 0.07% | N/A | N/A | N/A |
Debt/Assets
13.6%
Debt/Equity
0.18
Current Ratio
7.28
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 13.57% |
| 2026-03-31 | 13.45% |
| 2025-12-31 | 13.13% |
| 2025-09-30 | 12.47% |
| 2025-06-30 | 12.47% |
| 2025-03-31 | 12.25% |
| 2024-12-31 | 18.09% |
| 2024-09-30 | 16.68% |
| 2024-06-30 | 15.86% |
| 2024-03-31 | 17.22% |
| 2023-12-31 | 15.95% |
| 2023-09-30 | 15.11% |
| 2023-06-30 | 22.32% |
| 2023-03-31 | 20.25% |
| 2022-12-31 | 18.01% |
| 2022-09-30 | 15.97% |
| 2022-06-30 | 14.51% |
| 2022-03-31 | 12.87% |
| 2021-12-31 | 11.49% |
| 2021-09-30 | 10.51% |
| 2021-06-30 | 4.81% |
| 2021-03-31 | 4.54% |
| 2020-12-31 | 2.65% |
| 2020-09-30 | 2.51% |
| 2020-06-30 | 0.11% |
| 2020-03-31 | 0.12% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2018-12-31 | 0.00% |
